BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17498784)

  • 1. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
    Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
    Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
    Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
    Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
    Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
    Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
    Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
    Miyatake T; Tringler B; Liu W; Liu SH; Papkoff J; Enomoto T; Torkko KC; Dehn DL; Swisher A; Shroyer KR
    Gynecol Oncol; 2007 Jul; 106(1):119-27. PubMed ID: 17509674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
    Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-h4 is highly expressed in ductal and lobular breast cancer.
    Tringler B; Zhuo S; Pilkington G; Torkko KC; Singh M; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Clin Cancer Res; 2005 Mar; 11(5):1842-8. PubMed ID: 15756008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
    Høgdall CK; Nørgaard-Pedersen B; Mogensen O
    Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.
    Awadallah NS; Shroyer KR; Langer DA; Torkko KC; Chen YK; Bentz JS; Papkoff J; Liu W; Nash SR; Shah RJ
    Pancreas; 2008 Mar; 36(2):200-6. PubMed ID: 18376314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.